Last reviewed · How we verify

MK0954, /Duration of Treatment : 16 Weeks

Organon and Co · Phase 3 active Small molecule

MK0954, /Duration of Treatment : 16 Weeks is a Neurokinin-1 (NK1) receptor antagonist Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Chronic pain conditions (Phase 3 development).

MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.

MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system. Used for Chronic pain conditions (Phase 3 development).

At a glance

Generic nameMK0954, /Duration of Treatment : 16 Weeks
SponsorOrganon and Co
Drug classNeurokinin-1 (NK1) receptor antagonist
TargetNK1 receptor
ModalitySmall molecule
Therapeutic areaPain management / Neurology
PhasePhase 3

Mechanism of action

By antagonizing NK1 receptors, MK0954 inhibits the binding of substance P, a neuropeptide involved in pain transmission and emetic pathways. This mechanism is thought to provide analgesic and antiemetic effects. The drug crosses the blood-brain barrier to act on central NK1 receptors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MK0954, /Duration of Treatment : 16 Weeks

What is MK0954, /Duration of Treatment : 16 Weeks?

MK0954, /Duration of Treatment : 16 Weeks is a Neurokinin-1 (NK1) receptor antagonist drug developed by Organon and Co, indicated for Chronic pain conditions (Phase 3 development).

How does MK0954, /Duration of Treatment : 16 Weeks work?

MK0954 is a selective antagonist of the neurokinin-1 (NK1) receptor that blocks substance P signaling in the central nervous system.

What is MK0954, /Duration of Treatment : 16 Weeks used for?

MK0954, /Duration of Treatment : 16 Weeks is indicated for Chronic pain conditions (Phase 3 development).

Who makes MK0954, /Duration of Treatment : 16 Weeks?

MK0954, /Duration of Treatment : 16 Weeks is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is MK0954, /Duration of Treatment : 16 Weeks in?

MK0954, /Duration of Treatment : 16 Weeks belongs to the Neurokinin-1 (NK1) receptor antagonist class. See all Neurokinin-1 (NK1) receptor antagonist drugs at /class/neurokinin-1-nk1-receptor-antagonist.

What development phase is MK0954, /Duration of Treatment : 16 Weeks in?

MK0954, /Duration of Treatment : 16 Weeks is in Phase 3.

What are the side effects of MK0954, /Duration of Treatment : 16 Weeks?

Common side effects of MK0954, /Duration of Treatment : 16 Weeks include Headache, Dizziness, Nausea.

What does MK0954, /Duration of Treatment : 16 Weeks target?

MK0954, /Duration of Treatment : 16 Weeks targets NK1 receptor and is a Neurokinin-1 (NK1) receptor antagonist.

Related